deltatrials
Completed PHASE1 NCT00623831

A Phase 1 Study of Mixed Bacteria Vaccine (MBV) in Patients With Tumors Expressing NY-ESO-1 Antigen

A Phase 1 Study of Mixed Bacteria Vaccine (MBV) in Patients With Tumors Expressing NY-ESO-1 Antigen.

Sponsor: Krankenhaus Nordwest

Conditions Breast Cancer Esophageal Cancer Gastrointestinal Stromal Tumor (GIST) Head and Neck Cancer Melanoma Ovarian Carcinoma Prostate Cancer Sarcoma Transitional Cell Carcinoma
Interventions Mixed bacterial vaccine
Updated 7 times since 2017 Last updated: Oct 3, 2022 Started: May 31, 2007 Primary completion: May 31, 2012 Completion: May 31, 2013

Listed as NCT00623831, this PHASE1 trial focuses on Breast Cancer and Esophageal Cancer and remains completed. Sponsored by Krankenhaus Nordwest, it has been updated 7 times since 2007, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Change History

7 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE1

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE1

  3. Nov 2022 — Jul 2024 [monthly]

    Completed PHASE1

  4. Jan 2021 — Nov 2022 [monthly]

    Completed PHASE1

  5. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE1

▶ Show 2 earlier versions

  1. Feb 2017 — Jun 2018 [monthly]

    Completed PHASE1

  2. Jan 2017 — Feb 2017 [monthly]

    Completed PHASE1

    First recorded

May 2007

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Krankenhaus Nordwest
  • Ludwig Institute for Cancer Research
Data source: Ludwig Institute for Cancer Research

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • • Frankfurt, Germany